SLRN vs. MLYS, NRIX, VIR, NTLA, COLL, RCUS, RCKT, XNCR, ZYME, and XERS
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Zymeworks (ZYME), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.
Acelyrin vs.
Acelyrin (NASDAQ:SLRN) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership.
In the previous week, Mineralys Therapeutics had 11 more articles in the media than Acelyrin. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 2 mentions for Acelyrin. Acelyrin's average media sentiment score of 1.87 beat Mineralys Therapeutics' score of 0.89 indicating that Acelyrin is being referred to more favorably in the media.
Acelyrin presently has a consensus price target of $9.60, suggesting a potential upside of 286.32%. Mineralys Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 78.57%. Given Acelyrin's higher probable upside, research analysts plainly believe Acelyrin is more favorable than Mineralys Therapeutics.
Mineralys Therapeutics received 2 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.
Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
87.3% of Acelyrin shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 13.6% of Acelyrin shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Acelyrin has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Acelyrin's return on equity of -44.12% beat Mineralys Therapeutics' return on equity.
Summary
Mineralys Therapeutics beats Acelyrin on 8 of the 15 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
This page (NASDAQ:SLRN) was last updated on 3/31/2025 by MarketBeat.com Staff
